Autoimmune Haemolytic Anaemia
Autoimmune Haemolytic Anaemia Content
Sutimlimab potently inhibits the classical complement pathway, with efficacy against cold agglutinin disease
Cold agglutinin disease (CAD) is a rare haemolytic anaemia that causes fatigue, chronic inflammation and thromboembolic complications. Until recently, no therapies have been approved for CAD. Off-label rituximab – a B-cell depleting antibody – induces a short-lived partial response in around half of patients, and adding cytotoxic agents offer further benefit but at the price […]
Coming in from the cold: The phase III CASCADE trial of pegcetacoplan in cold agglutinin disease
In the burgeoning age of personalized medicine, the treatment of rare anaemias is being transformed from one relying on transfusions and general immunosuppressants to one targeting the underlying disease pathology. Rare anaemias currently experiencing this shift include the autoimmune haemolytic anaemia (AIHA) cold agglutinin disease (CAD), which results from the immune-mediated destruction of erythrocytes. A […]
Journal articles and more to your inbox
Get the latest clinical insights from touchHAEMATOLOGYSign me up!